LOPERAMIDE HYDROCHLORIDE Capsules (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Loperamide Hydrochloride 2 mg Hard Capsules.
Qualitative and quantitative composition
Each capsule contains 2 mg loperamide hydrochloride. Excipient with known effect: Each capsule contains 100 mg lactose monohydrate. For the full list of excipients, see section 6.1.
Pharmaceutical form
Capsule, hard. Hard gelatin capsules size 4 with a mauve opaque body and a dark green opaque cap. Marked LOPERA-MIDE 2 on the cap.
Therapeutic indications
For the symptomatic treatment of acute diarrhoea in adults and children aged 12 years and over. For the symptomatic treatment of acute episodes of diarrhoea associated with Irritable Bowel Syndrome in ...
Posology and method of administration
Posology Acute Diarrhoea Adults and children aged 12 years and over The initial dose is 2 capsules (4 mg), followed by 1 capsule after every subsequent loose stool. The usual dose is 3-4 capsules (6-8 ...
Contraindications
This medicine is contraindicated: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. In children under the age of 12 years old. In patients with acute dysentery, ...
Special warnings and precautions for use
Treatment of diarrhoea with loperamide HCl is only symptomatic. Whenever an underlying etiology can be determined, specific treatment should be given when appropriate. The priority in acute diarrhoea is ...
Interaction with other medicinal products and other forms of interaction
Non-clinical data have shown that loperamide is a P-glycoprotein substrate. Concomitant administration of loperamide (16 mg single dose) with quinidine, or ritonavir, which are both P-glycoprotein inhibitors, ...
Fertility, pregnancy and lactation
Pregnancy Safety in human pregnancy has not been established. Although from animal studies there are no indications that loperamide HCL possess any teratogenic or embryotoxic properties. As with other ...
Effects on ability to drive and use machines
Loss of consciousness, depressed level of consciousness, tiredness, dizziness or drowsiness may occur when diarrhoea is treated with loperamide HCl. Therefore, it is advisable to exercise caution when ...
Undesirable effects
Adults and children aged ≥12 years The safety of loperamide HCl was evaluated in 2755 adults and children aged ≥12 years who participated in 26 controlled and uncontrolled clinical trials of loperamide ...
Overdose
Symptoms In case of overdose (including relative overdose due to hepatic dysfunction), CNS depression (stupor, coordination abnormality, somnolence, miosis, muscular hypertonia, and respiratory depression), ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antipropulsives ATC code: A07DA03 By binding to opiate receptors in the gut wall, loperamide hydrochloride reduces propulsive peristalsis, increases intestinal transit time and ...
Pharmacokinetic properties
Absorption Most ingested loperamide is absorbed from the gut, but as a result of significant first pass metabolism, systemic bioavailability is only approximately 0.3%. Distribution Studies on distribution ...
Preclinical safety data
Acute and chronic studies on loperamide showed no specific toxicity. Results of in vivo and in vitro studies carried out indicated that loperamide is not genotoxic. In reproduction studies, very high doses ...
List of excipients
Each capsule contains: Lactose monohydrate Maize starch Magnesium stearate The capsule cap contains: Quinoline yellow (E104) Indigo carmine (E132) Titanium dioxide (E171) Gelatin The capsule body contains: ...
Incompatibilities
None known.
Shelf life
Shelf life Blisters: 5 years. Bottles: 4 years.
Special precautions for storage
Store below 25°C.
Nature and contents of container
Blister packaging in packs of 4, 6, 8, 10, 12, 16, 18, 20, 24, 28 and 30 capsules. Polypropylene pots with white polyethylene caps with optional polyethylene ullage fillers in packs of 4, 6, 8, 10, 12, ...
Special precautions for disposal and other handling
No special requirements. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Marketing authorization holder
Generics [UK] Limited t/a Mylan, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom
Marketing authorization number(s)
PL 04569/0201
Date of first authorization / renewal of the authorization
Date of first authorisation: 17 November 1987 Date of latest renewal: 29 March 2000
Date of revision of the text
March 2019
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
